Reverse redistribution-like change on dipyridamole-stress ^99mTc-tetrofosmin imaging in a patient with angiographically mild coronary artery stenosis

A 50-year-old man with a 1-month history of chest pain presented to our hospital. Transthoracic echocardiography showed normal left ventricular wall motion. Coronary computed tomography angiography revealed a mild stenosis with low-density non-calcified plaque in the proximal left anterior descending coronary artery (LAD) (Figure 1A, yellow arrows); therefore, the patient underwent a 1-day protocol of dipyridamole stress and rest ^99mTc-tetrofosmin myocardial perfusion imaging (MPI). Baseline electrocardiography was normal; however, he developed angina 8 minutes after the start of .56 mg·kg⁻¹ (.14 mg·kg⁻¹·min⁻¹ for 4 minutes) of intravenous dipyridamole infusion and his electrocardiogram showed ST-segment elevation in the precordial leads (Figure 2). After intravenous aminophylline with sublingual nitroglycerin was given, the ST-segment elevation was gradually resolved. Stress MPI showed no perfusion defect (Figure 1B) with abnormal wall motion in the anterior and septal walls on gated MPI (Supplementary Material). He had recurrent angina after the stress MPI. Rest MPI at 2 hours after the stress test showed reverse redistribution-like reduced uptake in the LAD territory (Figure 1B) with normal left ventricular wall motion on gated MPI (Supplementary Material). As with the coronary computed tomography, invasive coronary angiography via the right radial artery demonstrated the mild stenosis in the proximal LAD (Figure 3, yellow arrow). Intravascular ultrasound and optical coherence tomography images showed coronary plaque with neovascularization (Figure 3, red arrows) and small thrombi (Figure 3, white arrows) at the minimum lumen area site, indicating the increased vulnerability of the coronary plaque.1 Percutaneous coronary intervention (PCI) with a drug-eluting stent (4.0 × 33 mm) was successfully performed (Figure 3, red arrows). On the day following the PCI, he underwent cardiopulmonary exercise testing and did not present with chest pain at peak exercise (VO₂ at peak was 22.5 mL·kg⁻¹·min⁻¹ [6.4 METs]).

Intravenous dipyridamole and adenosine are widely used for pharmacological stress MPI to increase coronary blood flow. Previous studies reported that maximal coronary blood flow velocity is reached less quickly after the start of dipyridamole infusion than that of adenosine infusion (mean interval ± standard deviation, 287 ± 101 vs 55 ± 34 seconds; P < .0001),2 indicating that myocardial ischemia occurred after the tracer injection (7 minutes after the start of dipyridamole infusion) in this case. This case also suggested that dipyridamole-induced myocardial ischemia has a potentially harmful effect on vulnerable coronary plaque. Therefore, caution should be exercised when using dipyridamole for stress MPI.